Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Famous Brands six-month basic EPS drops 23% to 181 cents

Famous Brands six-month basic EPS drops 23% to 181 cents

BitgetBitget2026/10/21 05:12
  • Famous Brands' basic earnings per share fell 23% to 181 cents for the six months ended August 31, 2026.
  • Revenue rose to R 4.34 billion, while operating profit declined to R 375 million.
  • Cash generated by operations climbed 20% to R 564 million, while the interim dividend increased to 170 cents per share.
  • The group agreed to reduce its Botswana Retail Group stake from 51% to 30%, continuing its capital-light expansion strategy outside South Africa.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Famous Brands Ltd. published the original content used to generate this news brief via SENS, the regulatory disclosure system operated by the Johannesburg Securities Exchange (JSE) (Ref. ID: S605295), on October 21, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

PoolX: Locked for new tokens.
APR up to 10%. Always on, always get airdrop.
Lock now!

You may also like

Profit surges; amid concerns over U.S. surgical volume, JPMorgan maintains "Overweight" on Intuitive Surgical (ISRG.US) and raises target price to $475

Intuitive Surgical (ISRG.US), the global leader in surgical robots, released its Q3 2026 earnings report on October 20 (U.S. Eastern Time). On the same day, JPMorgan published a research report, maintaining an "Overweight" rating on the stock.

智通财经•2026/10/21 07:13

Allergy and autoimmune biotechnology company Lycia Therapeutics (LYCA.US) sets IPO price at $16-18 per share, plans to raise $250 million

Lycia Therapeutics announced the terms of its initial public offering (IPO) on Tuesday.

智通财经•2026/10/21 07:06